

# Early Palliative Care Improves Overall Survival in Patients With Lymphoma: A Single-institution Retrospective Study

MISAKI MORISAKU<sup>1,2\*</sup>, KAORI ITO<sup>1,2,3\*</sup>, TATSUKI SHIMOMURA<sup>1,2</sup>, SHOKO MAEDA<sup>4</sup>,  
MAIKO MORI<sup>2,3</sup>, SEIRA TOYOSATO<sup>1</sup>, YOSUKE ANDO<sup>1</sup>, TAKENAO KOSEKI<sup>1</sup>,  
MASAMI KAWAHARA<sup>4</sup>, AKIHIRO TOMITA<sup>3</sup> and SHIGEKI YAMADA<sup>1,2</sup>

<sup>1</sup>Department of Clinical Pharmacy, Fujita Health University, Toyoake, Japan;

<sup>2</sup>Department of Pharmacy, Fujita Health University Hospital, Toyoake, Japan;

<sup>3</sup>Department of Hematology, Fujita Health University School of Medicine, Toyoake, Japan;

<sup>4</sup>School of Pharmacy, Aichi Gakuin University, Nagoya, Japan

**Abstract.** *Background/Aim:* Early palliative care (EPC) intervention in patients with solid tumors can provide many benefits. However, studies on patients with hematological malignancies are limited, and there is no data on patients with lymphoma. We conducted a preliminary retrospective survey of palliative care (PC) intervention in patients with lymphoma to clarify the effect of EPC on overall survival (OS). *Patients and Methods:* The first palliative care consultation (PCI) was retrospectively reviewed from medical records in Japan. Patients with lymphoma requiring inpatient PC at our institution from January 2012 to December 2018 were recruited. We conducted receiver operating characteristic (ROC) analysis; patients were divided into two groups (early and delayed), and the survival periods and palliative care team (PCT) referral details were compared. *Results:* The analysis included 77 patients with lymphoma [median age, 71 (64-79)] years. The median period to PCI from the initial diagnosis was 395 (180-1,086) days. ROC analysis revealed an optimal PC intervention timing of 140 days. OS was significantly longer in the early group than that in the delayed group. The most common

counseling details for the PCT were symptom relief and palliative care transfer (36.8% and 35.2%, respectively). *Conclusion:* This real-world evaluation of PC intervention for inpatients with lymphoma revealed that PC intervention was provided at approximately 13 months following initial diagnosis. EPC intervention from diagnosis to 140 days may improve OS in patients with lymphoma; however further large-scale studies are required to verify this finding.

Reports from Europe and the United States have indicated that the median survival is significantly longer in patients with metastatic non-small cell lung cancer who receive early palliative care (EPC) intervention compared with patients without EPC intervention, demonstrating the effectiveness of EPC intervention in patients with lung cancer (1, 2). EPC intervention is associated with various benefits, including improvements in symptoms, quality of life (QOL), mood and distress, patient satisfaction as well as benefits for caregivers (3-9). A 2015 study found that the 1-year survival rate of patients with cancer was significantly improved following EPC intervention compared with delayed intervention after 3 months (10). However, only 10 (4.8%) of 207 patients evaluated in this study were diagnosed with a hematologic malignancy (HM), which limits the accurate evaluation of the effects of EPC intervention on the survival of patients with HM.

Several arguments have been made concerning the complexity of palliative care (PC) intervention and the intervention timing in patients with HM (11-18). However, the optimal timing of palliative intervention has not been determined.

Regarding PC interventions in HMs, some studies have reported that they improved QOL and decreased psychological distress in patients with hematopoietic stem-cell transplants (19-21). Others report improved pain in patients with multiple myeloma (22) and improved QOL in

\*These Authors contributed equally to this study.

*Correspondence to:* Kaori Ito, Ph.D., Department of Pharmacy, Fujita Health University Hospital, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan. Tel: +81 562932149, Fax: +81 562934537, e-mail: itoka@fujita-hu.ac.jp

*Key Words:* Palliative care, early intervention, lymphoma, overall survival.



This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY-NC-ND) 4.0 international license (<https://creativecommons.org/licenses/by-nc-nd/4.0>).

Disease name

Metastasis  Present  Absent  Other

If present

Consult details  Symptom relief...  Pain  General malaise  Respiratory distress  Nausea  
 Loss of appetite

Psychological manifestations...  Anxiety  Delirium  Depression  Insomnia

Palliative care ward transfer ...  Our hospital  Other hospital

Adjustment for home care

Other

Future treatment plan:  Surgery  Chemotherapy  Radiotherapy  Palliative care

Other

Prognosis prediction by the physician:  Less than 1 week  1 week to 1 month  
 1–2 months  2–3 months  ≥ 3 months  Unknown  Other

Place of future medical treatment:  Ongoing hospitalization  Hospital transfer  Home  
 Palliative care ward  Other

Disease notification:  Full notification  Partial notification  No notification  Other

DNAR consent:  Yes  No  Other

Other: Please describe the history of present illness that should be noted, and main wishes for intervention

Figure 1. Request form for the inpatient palliative care team. The attending physician submits consultation requests for the palliative care team via the electronic medical record using this form. Information provided includes the disease name, consultation details, future treatment plan, prognosis prediction by the physician, place of future medical treatment, disease notification, and do-not-attempt-resuscitation consent.

patients with acute myeloid leukemia (23). However, there are no reports of patients with lymphoma. Here, we reviewed the medical records of patients with lymphoma at a single institution to elucidate the timing of PC counseling requests, consult details, and the effects of PC intervention on patient survival.

### Patients and Methods

**Subjects.** We included inpatients with HMs who consulted the palliative care team (PCT) of our hospital between January 2012 and December 2018. Patients for whom the date of diagnosis of HM was unclear and patients with diseases other than lymphoma were excluded. All procedures in this study including human participants were performed in accordance with the ethical standards of our institution and of Japanese study groups, as well as the principles of the Declaration of Helsinki of 1964 and its later amendments. The present study was approved by the Institutional Review Board

for Medical Research of the Fujita Health University School of Medicine and Aichi Gakuin University. (Approval Code of Institutional Review Board for Medical Research of the Fujita Health University School of Medicine: HM20-017).

**Investigation.** We collected the following demographic information from the patients' electronic medical records: age, sex, height, weight, body surface area, body mass index, date of HM diagnosis, disease name, disease type, performance status, presence or absence of relapse, and presence or absence of a do-not-attempt-resuscitation (DNAR) order acquired at the first PCT consultation (PC1). The date of death, number of days to PC1 since the diagnosis date, number of consultations, consultation details, presence or absence of transfusion, final transfusion date, and date of final chemotherapy were retrospectively examined.

**Palliative care intervention.** To consult the PCT, the inpatient attending physician or ward staff, upon receiving instructions, created a PCT request form and contacted the PCT. Figure 1

shows the details of the request form. The PCT reviewed the request form. The team consisted of a PC physician, nurse, pharmacist, and clinical psychologist. The PCT followed patients longitudinally during their hospitalization and saw them at least twice per week.

**Evaluation methods.** The reasons for patient referrals to the PCT were identified and the most common reason for referral was determined. Based on the receiver operating characteristic (ROC) analysis, subjects were divided into early and late intervention groups. The DNAR status at the time of the consultation, transfusion, date of final chemotherapy, and survival period following submission of the request form were compared between groups.

**Analysis.** Values indicating nonnormal distribution are shown as medians and interquartile ranges. Items with nonnormal distribution are expressed as medians (quartiles). The ROC analysis was used to calculate the cutoff for survival and PC interventions. Analyses were performed using unpaired tests to compare the two groups, including chi-squared or Mann-Whitney *U*-tests, with Cox's proportional hazards model (multiple regression analysis) to calculate the hazard ratio to assess the survival period with a 95% confidence interval. We used R software (The R Foundation for Statistical Computing, Vienna, Austria; version 2.13.0) for all statistical analyses. A *p*-value of <0.05 was considered to indicate a statistically significant difference.

## Results

**Determining palliative care intervention timing.** We set the survival time at 120 days from the PC1 and analyzed the relationship between PC timing and survival using ROC analysis (Figure 2). The results were similar for 150 days and 180 days (data not shown). The ROC analysis revealed a cutoff value for the PC intervention period of 139 days from diagnosis. Based on these results, we determined that the optimal timing of palliative intervention was 140 days.

**Patient background.** Among 151 inpatients with HMs for whom the PCT was consulted during the study period, we excluded 10 patients with unknown dates of HM diagnosis and three patients with diseases other than leukemia, lymphoma, myeloma. We excluded 36 patients with leukemia and 25 with myeloma. Ultimately, 77 patients with lymphoma were included in the analysis. Table I shows the demographic and clinical characteristics of the 77 patients. The median period from the initial diagnosis date to PC1 was 395 (180-1,086) days; the median period was 27 (10-73) days in the early group and 601 (300-1,570) days in the delayed group, indicating a significantly shorter time to consultation in the early group. The early group consisted mostly of patients with B symptom and without relapse compared with the delayed group. Among the 38 patients with relapse, request forms were submitted prior to relapse for three patients, at the time of relapse for one patient, and after relapse for 34 (89.4%) patients. The




Figure 2. Receiver operating characteristic (ROC) curve analysis of time to consultation request submission for patients with lymphoma. For patients surviving 120 days after palliative care referral: cut-off, 139 days; sensitivity, 0.714; specificity, 0.818; AUC=0.699 (95%CI=0.449-0.949).

median period from relapse to the day of consultation was 115 (71-314) days.

**Intergroup comparison of the overall survival period.** Figure 3 demonstrates the survival curve from consultation submission to death in patients with lymphoma. Comparison of the early and delayed groups revealed a longer survival period for the early group, as indicated by the dotted line.

**Multiple regression analysis of factors that contribute to survival between the two groups.** We performed a multiple regression analysis using a Cox proportional hazards model adjusted for survival as an outcome variable and age, performance status, the presence or absence of relapse, clinical stage, and body mass index as covariates (Table II). A survival hazard ratio of 0.33 and early PC intervention from diagnosis to 140 days were found to significantly reduce mortality in patients with lymphoma.

**Reasons for referrals to the palliative care team.** Table III lists the reasons for referrals to the PCT. Among the 77 patients, there were a total of 125 consultations (including overlapping responses). Among the reasons for referrals, physical symptom relief was most common in the early group, and physical symptom relief and transfer to a PC

Table I. Patient background information.

Demographics	Total (n=77)	Early group (n=18)	Late group (n=59)	p-Value
Age, median (IQR)	71.0 (64.0, 79.0)	74.0 (67.2, 77.7)	70.0 (63.0, 79.5)	0.621
Male, no (%)	39 (50.6)	10 (55.6)	29 (49.2)	0.789
BMI, median (IQR)	19.6 (17.3, 21.9)	21.0 (18.9, 22.3)	19.4 (17.2, 21.7)	0.315
PS, no (%)				
2/≥3	3 (3.9)/74 (96.1)	0 (0)/18 (100.0)	3 (5.1)/56 (94.9)	1.000
Stage, no (%)				
1,2/≥3	8 (10.7)/67 (89.3)	1 (5.9)/16 (94.1)	7 (12.1)/51 (87.9)	0.674
Clinical classification, no (%)				
DLBCL	40 (51.9)	9 (50.0)	31 (52.5)	0.083
FL	10 (13.0)	0 (0.0)	10 (17.0)	
BL	2 (2.6)	1 (5.6)	1 (1.7)	
IVL	1 (1.3)	1 (5.6)	0 (0.0)	
LPL	4 (5.2)	2 (11.1)	2 (3.4)	
MCL	4 (5.2)	1 (5.6)	3 (5.1)	
AITL	2 (2.6)	0 (0.0)	2 (3.4)	
ATLL	4 (5.2)	0 (0.0)	4 (6.8)	
NK/T cell lymphoma	1 (1.3)	0 (0.0)	1 (1.7)	
PTCL	6 (7.8)	3 (16.7)	3 (5.1)	
T cell lymphoma	1 (1.3)	0 (0.0)	1 (1.7)	
HL	1 (1.3)	0 (0.0)	1 (1.7)	
ML (unknown)	1 (1.3)	1 (5.6)	0 (0.0)	
B symptom, no (%)	38 (50.0)	14 (82.4)	24 (40.7)	0.005
Relapse, no (%)	38 (49.4)	2 (11.1)	36 (61.0)	<0.001
Days from diagnosis to consult request submission, median (IQR)	395 (180, 1,086)	27 (10, 73)	601 (300, 1,570)	<0.001

IQR: Interquartile range; BMI: body mass index; PS: performance status; DLBCL: diffuse large B-cell lymphoma; FL: follicular lymphoma; BL: Burkitt lymphoma; IVL: intravascular lymphoma; LPL: lymphoplasmacytic lymphoma; MCL: mantle cell lymphoma; AITL: angioimmunoblastic T-cell lymphoma; ATLL: adult T-cell leukemia/lymphoma; NK: natural killer; PTCL: peripheral T-cell lymphoma; HL: Hodgkin lymphoma; ML: malignant lymphoma.

ward were the most common in the delayed group. Among the referrals for symptom relief, pain was the most common symptom in the early group and general malaise was the most common in the delayed group. Regarding the psychological manifestations, anxiety and depression were highest in the early group and the ratios of anxiety, insomnia, and delirium were similar in the delayed group.

**DNAR consent acquisition.** At the time of consultation with the PCT, DNAR consent had been obtained from 50 of 77 patients (64.9%). Consent had not been obtained from 14 patients (18.1%) and data were missing for 13 patients (16.8%). Intergroup comparison between the early and delayed groups revealed that DNAR consent had been obtained from 12 and 38 patients, but not obtained from five and nine patients, respectively. There was no statistically significant difference between the two groups ( $p=0.21$ ).

**Transfusion.** Of 77 patients, 63 patients (81.8%) received a transfusion, and 14 patients (18.1%) did not. The consultation request for a PCT was made prior to or on the day of the final transfusion in 36 patients, which is

Table II. Cox proportional hazards model.

	HR	95%CI	p-Value
Request early <140	0.3319	0.16-0.67	0.0022
Age	1.016	0.99-1.042	0.22
PS ≥3	1.794	0.48-6.66	0.38
Relapse	0.5502	0.32-0.94	0.032
Stage ≥3	0.7776	0.33-1.807	0.55
BMI	0.9647	0.88-1.053	0.42

HR: Hazard ratio; 95%CI: 95% confidence interval; PS: performance status; BMI: body mass index.

equivalent to 57.1% of patients who underwent a transfusion. The median period from PC1 to the day of the final transfusion was 523 (190-1,121) days. A total of 27 (42.8%) patients requested a PCT consultation after their final transfusion. Among 63 patients who received transfusion, the median period from the final transfusion day to the last date of confirmed survival was 21 (7-76) days. Transfusion was performed in 13 (20.6%) and 50 patients (79.4%) in the early




Figure 3. Overall survival curve in delayed and early groups. The survival curve for patients with hematologic malignancies from consultation submission to death. The black dotted line represents the early group; the black line represents the delayed group. The adjusted hazard ratio was calculated using a Cox proportional hazards model (covariates: age, performance status, presence or absence of relapse, stage, and body mass index). AUC: Area under the curve; CI: confidence interval.

and delayed groups, respectively. The delayed group had a significantly higher proportion of patients who received transfusion ( $p < 0.05$ ).

**Final chemotherapy.** Data regarding the final day of chemotherapy administration was available for 70 of 77 patients (90.9%). A PCT consultation request was made on or before the final chemotherapy treatment for 19 patients (27.1%). Among these patients, the period between PC1 and the last chemotherapy treatment was  $\leq 1$  week in 10 patients (52.6%), and a total of nine patients (47.3%) received their final chemotherapy administration within one week of PCT consultation. The median period from PC1 to the final chemotherapy administration day was nine (2-109) days. Overall, 51 patients (72.8%) requested a PCT consultation

after their final chemotherapy administration, and three-quarters of request forms were submitted after the final chemotherapy administration. In the between-group comparison, the percentages of requests submitted before the final chemotherapy administration were not significantly different between the early [6/14 (42.8%)] and delayed groups [13/56 (23.2%)] ( $p = 0.353$ ).

## Discussion

The present study found, through a retrospective review of hospital records, that the median period from the initial diagnosis until the first inpatient consultation for PCT intervention was 395 (180-1,086) days in patients with lymphoma. In a comparison of the two groups using a 140-

Table III. Reasons for referral to the palliative care team.

Reasons for referral to the PCT	Total (n=77)	Early group (n=18)	Delayed group (n=59)
Referral, no	125	31	94
Symptom relief, no (%)	46 (36.8)	12 (38.7)	34 (36.1)
Palliative care ward transfer, no (%)	44 (35.2)	10 (32.2)	34 (36.1)
Psychological manifestations, no (%)	22 (17.6)	6 (19.3)	16 (17.0)
Adjustment for home care, no (%)	4 (3.2)	1 (3.2)	3 (3.1)
Others, no (%)	9 (7.2)	2 (6.4)	7 (7.4)
Symptom relief, no	77	19	58
General malaise, no (%)	28 (36.3)	5 (26.3)	23 (39.6)
Pain, no (%)	27 (35.0)	7 (36.8)	20 (34.4)
Respiratory distress, no (%)	13 (16.8)	5 (26.3)	8 (13.7)
Loss of appetite, no (%)	5 (6.4)	1 (5.2)	4 (6.8)
Nausea, no (%)	4 (5.1)	1 (5.2)	3 (5.1)
Psychological manifestations, no	27	9	18
Anxiety, no (%)	10 (37.0)	3 (33.3)	7 (38.8)
Insomnia, no (%)	7 (25.9)	2 (22.2)	5 (27.7)
Delirium, no (%)	6 (22.2)	1 (11.1)	5 (27.7)
Depression, no (%)	4 (14.8)	3 (33.3)	1 (5.5)

PCT: Palliative care team.

day cutoff from diagnosis to palliative intervention, the early group showed a significant prolongation of the survival curve compared with the delayed group. The most common reason for a PCT consultation was symptom alleviation at [46 of 125 (36.8%)], and the main symptoms were general malaise and pain. The second most common reason was to request transfer to the palliative care ward (35.2%), followed by psychological support (17.6%). We suggest that early intervention by PCT, including symptom relief, transfer to a palliative care ward, and psychological support, may lead to improved prognosis in patients with lymphoma.

Compared with the delayed group, the early group had a higher proportion of referrals for symptom relief. Pain was the most frequent among the symptoms, suggesting that early pain control interventions by a PCT may be important even in patients with lymphoma. In addition, the early group had high proportions of anxiety and depression, as well as pain control by PCT, indicating that early intervention of psychological manifestations may lead to prolonged OS. Compared with the early group, the delayed group had a higher proportion of referrals for palliative care ward transfer, general malaise, and delirium, suggesting worsened general condition. PCT referral in the early stage before the appearance of delirium may lead to improved OS.

Regarding HMs, administration of transfusion therapy and palliative chemotherapy may limit transfer to the palliative ward. In the study by Odejide *et al.* including a sample of hematologic oncologists, the majority strongly agreed that hospice care is helpful for patients with HMs. Otherwise, participants who considered home hospice to be inadequate were more likely to report an increase in the number of

referrals if transfusions were readily available (24). Indeed, the American Society of Hematology released a statement recommending that hospice agencies and payers work collaboratively to ensure the availability of palliative transfusions to optimize end of life care for patients with HMs (25). Similarly, many end-stage patients with HMs in Japan may find it difficult to transfer to a palliative care ward because of the high cost of dependent blood transfusions. In our study, although there was no significant difference in the acquisition of DNAR or the presence or absence of chemotherapy, the delayed group had a significantly higher proportion of patients who received transfusion. Improving the use of blood transfusions in palliative care wards for HMs may lead to EPC interventions and prolonged patient survival.

While various randomized trials have demonstrated the benefits of providing oncology patients with PC support, the optimal timing for PC intervention has remained unclear. Thus, Bakitas *et al.* conducted a randomized trial examining the impact of early and delayed PC intervention on QOL, symptoms, mood, 1-year survival, and resource usage (10). They defined early PC intervention as 30-60 days from diagnosis and delayed intervention as later than 3 months from diagnosis, based on their previous findings from the ENABLE II trial. They set 3 months as the threshold for delayed intervention based on the feedback that patients experiencing enormous stress from symptoms benefitted from PC at that point. In the report by Bakitas *et al.* the intensity of symptoms had significantly increased by 3 months following diagnosis (26, 27). In our study, the median period until PC intervention from initial diagnosis

was 13.1 months. Based on the ROC analysis, we determined that the timing of palliative intervention was 140 days, which is still longer than that in the delayed group in the study by Bakitas *et al*. Notably, in the ENABLE II trial, the subjects presented with advanced solid tumors, and patients with HMs were not included. As with patients with solid tumors, EPC is thought to have a positive effect, although the timing should be considered separately for solid tumors and HMs owing to their specificity. In this study, we believe that determining the appropriate PC timings using ROC analysis in patients with HMs will be helpful for improving the overall survival.

This study has several limitations. First, submission of the request form to the PCT was defined as the initial PC intervention (PC1). The interventions performed by the PCT after the referral and their evaluation not surveyed. Second, treatment, procedures, and support corresponding to palliative care, thus far, have been performed by hematologists, and staff specializing in hematology who were included in the general medical care were not included. The PCT intervention was considered a specialist PC intervention. Third, this was a single-center retrospective study; therefore, interinstitutional differences such as the method of requests to PCT, criteria for PC ward transfer, and medical care that can be provided in the palliative care ward were not examined, making it difficult to exclude all biases. In this study, it was not possible to conduct a detailed examination of lymphoma types, treatment regimens, and the presence or absence of recurrence; therefore, further detailed studies including disease types and treatment regimens are required.

## Conclusion

Real-world evaluation of PC intervention for inpatients with lymphoma revealed that PCT intervention was provided at approximately 13 months following initial diagnosis. EPC interventions up to 140 days after diagnosis may lead to pain control, relief of psychological stress, early transfer to an appropriate PC ward, and may improve prognosis in patients with lymphoma. This was a retrospective study that included a small number of cases at a single hospital; therefore, further detailed trials are required.

## Conflicts of Interest

There are no conflicts of interest to declare regarding the publication of this study.

## Authors' Contributions

Conceptualization: Misaki Morisaku, Kaori Ito, Takenao Koseki. Data curation: Misaki Morisaku, Tatsuki Shimomura. Formal analysis: Kaori Ito, Takenao Koseki. Investigation: Misaki

Morisaku, Maiko Mori, Tatsuki Shimomura, Shoko Maeda. Methodology: Kaori Ito, Takenao Koseki. Supervision: Seira Toyosato, Yosuke Ando, Masami Kawahara, Akihiro Tomita. Writing – original draft: Misaki Morisaku, Kaori Ito. Writing – review & editing: Kaori Ito, Masami Kawahara, Akihiro Tomita, Shigeki Yamada.

## Acknowledgements

The Authors would like to thank Editage (<https://www.editage.com/>) for English editing services.

## References

- 1 Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, Dahlin CM, Blinderman CD, Jacobsen J, Pirl WF, Billings JA and Lynch TJ: Early palliative care for patients with metastatic non-small-cell lung cancer. *N Engl J Med* 363(8): 733-742, 2010. PMID: 20818875. DOI: 10.1056/NEJMoa1000678
- 2 Temel JS, Greer JA, Admane S, Gallagher ER, Jackson VA, Lynch TJ, Lennes IT, Dahlin CM and Pirl WF: Longitudinal perceptions of prognosis and goals of therapy in patients with metastatic non-small-cell lung cancer: results of a randomized study of early palliative care. *J Clin Oncol* 29(17): 2319-2326, 2011. PMID: 21555700. DOI: 10.1200/JCO.2010.32.4459
- 3 Zimmermann C, Swami N, Krzyzanowska M, Hannon B, Leigh N, Oza A, Moore M, Rydall A, Rodin G, Tannock I, Donner A and Lo C: Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial. *Lancet* 383(9930): 1721-1730, 2014. PMID: 24559581. DOI: 10.1016/S0140-6736(13)62416-2
- 4 El-Jawahri A, LeBlanc T, VanDusen H, Traeger L, Greer JA, Pirl WF, Jackson VA, Telles J, Rhodes A, Spitzer TR, McAfee S, Chen YA, Lee SS and Temel JS: Effect of inpatient palliative care on quality of life 2 weeks after hematopoietic stem cell transplantation: a randomized clinical trial. *JAMA* 316(20): 2094-2103, 2016. PMID: 27893130. DOI: 10.1001/jama.2016.16786
- 5 Grudzen CR, Richardson LD, Johnson PN, Hu M, Wang B, Ortiz JM, Kistler EA, Chen A and Morrison RS: Emergency department-initiated palliative care in advanced cancer: a randomized clinical trial. *JAMA Oncol* 2(5): 591-598, 2016. PMID: 26768772. DOI: 10.1001/jamaoncol.2015.5252
- 6 Temel JS, Greer JA, El-Jawahri A, Pirl WF, Park ER, Jackson VA, Back AL, Kamdar M, Jacobsen J, Chittenden EH, Rinaldi SP, Gallagher ER, Eusebio JR, Li Z, Muzikansky A and Ryan DP: Effects of early integrated palliative care in patients with lung and GI cancer: a randomized clinical trial. *J Clin Oncol* 35(8): 834-841, 2017. PMID: 28029308. DOI: 10.1200/JCO.2016.70.5046
- 7 Bakitas M, Lyons KD, Hegel MT, Balan S, Brokaw FC, Seville J, Hull JG, Li Z, Tosteson TD, Byock IR and Ahles TA: Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: the Project ENABLE II randomized controlled trial. *JAMA* 302(7): 741-749, 2009. PMID: 19690306. DOI: 10.1001/jama.2009.1198
- 8 Dionne-Odom JN, Azuero A, Lyons KD, Hull JG, Tosteson T, Li Z, Li Z, Frost J, Dragnev KH, Akyar I, Hegel MT and Bakitas

- MA: Benefits of early *versus* delayed palliative care to informal family caregivers of patients with advanced cancer: outcomes from the ENABLE III randomized controlled trial. *J Clin Oncol* 33(13): 1446-1452, 2015. PMID: 25800762. DOI: 10.1200/JCO.2014.58.7824
- 9 McDonald J, Swami N, Hannon B, Lo C, Pope A, Oza A, Leigh N, Krzyzanowska MK, Rodin G, Le LW and Zimmermann C: Impact of early palliative care on caregivers of patients with advanced cancer: cluster randomised trial. *Ann Oncol* 28(1): 163-168, 2017. PMID: 27687308. DOI: 10.1093/annonc/mdw438
  - 10 Bakitas MA, Tosteson TD, Li Z, Lyons KD, Hull JG, Li Z, Dionne-Odom JN, Frost J, Dragnev KH, Hegel MT, Azuero A and Ahles TA: Early *versus* delayed initiation of concurrent palliative oncology care: Patient outcomes in the ENABLE III randomized controlled trial. *J Clin Oncol* 33(13): 1438-1445, 2015. PMID: 25800768. DOI: 10.1200/JCO.2014.58.6362
  - 11 Auret K, Bulsara C and Joske D: Australasian haematologist referral patterns to palliative care: lack of consensus on when and why. *Intern Med J* 33(12): 566-571, 2003. PMID: 14656229. DOI: 10.1111/j.1445-5994.2003.00490.x
  - 12 Newton S: Haematology and palliative care: blood, sweat and tears. *Intern Med J* 33(12): 549-551, 2003. PMID: 14656224. DOI: 10.1111/j.1445-5994.2003.00499.x
  - 13 Mander T: Haematology and palliative care: an account of shared care for a patient undergoing bone marrow transplantation for chronic myeloid leukaemia. *Int J Nurs Pract* 3(1): 62-66, 1997. PMID: 9274219. DOI: 10.1111/j.1440-172x.1997.tb00073.x
  - 14 Kelly D, Ross S, Gray B and Smith P: Death, dying and emotional labour: problematic dimensions of the bone marrow transplant nursing role? *J Adv Nurs* 32(4): 952-960, 2000. PMID: 11095235.
  - 15 Daugherty CK and Steensma DP: Overcoming obstacles to hospice care: an ethical examination of inertia and inaction. *J Clin Oncol* 21(9 Suppl): 42s-45s, 2003. PMID: 12743190. DOI: 10.1200/JCO.2003.01.167
  - 16 Selvaggi KJ, Vick JB, Jessell SA, Lister J, Abrahm JL and Bernacki R: Bridging the gap: a palliative care consultation service in a hematological malignancy-bone marrow transplant unit. *J Community Support Oncol* 12(2): 50-55, 2014. PMID: 24971405. DOI: 10.12788/jcso.0015
  - 17 Chung HM, Lyckholm LJ and Smith TJ: Palliative care in BMT. *Bone Marrow Transplant* 43(4): 265-273, 2009. PMID: 19151797. DOI: 10.1038/bmt.2008.436
  - 18 Manitta VJ, Philip JA and Cole-Sinclair MF: Palliative care and the hemato-oncological patient: can we live together? A review of the literature. *J Palliat Med* 13(8): 1021-1025, 2010. PMID: 20712465. DOI: 10.1089/jpm.2009.0267
  - 19 Loggers ET, LeBlanc TW, El-Jawahri A, Fihn J, Bumpus M, David J, Horak P and Lee SJ: Pretransplantation supportive and palliative care consultation for high-risk hematopoietic cell transplantation patients. *Biol Blood Marrow Transplant* 22(7): 1299-1305, 2016. PMID: 26976242. DOI: 10.1016/j.bbmt.2016.03.006
  - 20 El-Jawahri A, LeBlanc T, VanDusen H, Traeger L, Greer JA, Pirl WF, Jackson VA, Telles J, Rhodes A, Spitzer TR, McAfee S, Chen YA, Lee SS and Temel JS: Effect of inpatient palliative care on quality of life 2 weeks after hematopoietic stem cell transplantation: a randomized clinical trial. *JAMA* 316(20): 2094-2103, 2016. PMID: 27893130. DOI: 10.1001/jama.2016.16786
  - 21 El-Jawahri A, Traeger L, Greer JA, VanDusen H, Fishman SR, LeBlanc TW, Pirl WF, Jackson VA, Telles J, Rhodes A, Li Z, Spitzer TR, McAfee S, Chen YA and Temel JS: Effect of inpatient palliative care during hematopoietic stem-cell transplant on psychological distress 6 months after transplant: results of a randomized clinical trial. *J Clin Oncol* 35(32): 3714-3721, 2017. PMID: 28926288. DOI: 10.1200/JCO.2017.73.2800
  - 22 Porta-Sales J, Guerrero-Torrelles M, Moreno-Alonso D, Sarrà-Escarré J, Clapés-Puig V, Trelis-Navarro J, Sureda-Balarí A and Fernández De Sevilla-Ribosa A: Is early palliative care feasible in patients with multiple myeloma? *J Pain Symptom Manage* 54(5): 692-700, 2017. PMID: 28807703. DOI: 10.1016/j.jpainsymman.2017.04.012
  - 23 El-Jawahri A, LeBlanc TW, Kavanaugh A, Webb JA, Jackson VA, Campbell TC, O'Connor N, Luger SM, Gafford E, Gustin J, Bhatnagar B, Walker AR, Fathi AT, Brunner AM, Hobbs GS, Nicholson S, Davis D, Addis H, Vaughn D, Horick N, Greer JA and Temel JS: Effectiveness of integrated palliative and oncology care for patients with acute myeloid leukemia: a randomized clinical trial. *JAMA Oncol* 7(2): 238-245, 2021. PMID: 33331857. DOI: 10.1001/jamaoncol.2020.6343
  - 24 Odejide OO, Cronin AM, Earle CC, Tulskey JA and Abel GA: Why are patients with blood cancers more likely to die without hospice? *Cancer* 123(17): 3377-3384, 2017. PMID: 28542833. DOI: 10.1002/cncr.30735
  - 25 American Society of Hematology: ASH Statement in Support of Palliative Blood Transfusions in Hospice Setting. Washington, DC, 2019. Available at: <https://www.hematology.org/advocacy/policy-news-statements-testimony-and-correspondence/policy-statements/2019/palliative-blood-transfusions-in-hospice> [Last accessed on November 2, 2020]
  - 26 Maloney C, Lyons KD, Li Z, Hegel M, Ahles TA and Bakitas M: Patient perspectives on participation in the ENABLE II randomized controlled trial of a concurrent oncology palliative care intervention: benefits and burdens. *Palliat Med* 27(4): 375-383, 2013. PMID: 22573470. DOI: 10.1177/0269216312445188
  - 27 Bakitas M, Lyons KD, Hegel MT, Balan S, Barnett KN, Brokaw FC, Byock IR, Hull JG, Li Z, McKinstry E, Seville JL and Ahles TA: The project ENABLE II randomized controlled trial to improve palliative care for rural patients with advanced cancer: baseline findings, methodological challenges, and solutions. *Palliat Support Care* 7(1): 75-86, 2009. PMID: 19619377. DOI: 10.1017/S1478951509000108

Received August 14, 2022  
 Revised August 29, 2022  
 Accepted August 30, 2022